AW
TNGX icon

Alaethes Wealth’s Tango Therapeutics TNGX Stock Holding History

Alaethes Wealth’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,000
Closed -$85.8K – 117
2024
Q2 		$85.8K Hold
10,000
– – 0.04% 108
2024
Q1 		$79.4K Sell
10,000
-10,000
-50% -$107K 0.03% 110
2023
Q4 		$198K Hold
20,000
– – 0.09% 113
2023
Q3 		$225K Hold
20,000
– – 0.12% 105
2023
Q2 		$66.4K Hold
20,000
– – 0.04% 108
2023
Q1 		$79K Hold
20,000
– – 0.05% 108
2022
Q4 		$145K Hold
20,000
– – 0.1% 103
2022
Q3 		$72K Hold
20,000
– – 0.05% 99
2022
Q2 		$91K Buy
+20,000
New +$121K 0.07% 101
2021
Q3 		– Sell
-20,000
Closed -$228K – 283
2021
Q2 		$228K Hold
20,000
– – 0.18% 85
2021
Q1 		$222K Buy
+20,000
New +$230K 0.21% 86

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Alaethes Wealth's TNGX Position: Q3 2024 in Review

Alaethes Wealth sold out of Tango Therapeutics (TNGX) in Q3 2024, closing a stake of 10,000 shares — an estimated $85.8K sold.

Alaethes Wealth first reported a position in TNGX in Q1 2021 and held it in 11 quarters. The position peaked at $228K in Q2 2021. 121 funds tracked by Wall St. Rank hold TNGX as of Q3 2024.

  • Alaethes Wealth reported no remaining Tango Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Alaethes Wealth sold 10,000 Tango Therapeutics shares in Q3 2024, an estimated $85.8K.
  • Alaethes Wealth first reported a position in Tango Therapeutics in Q1 2021 and held it in 11 quarters.
  • Alaethes Wealth's Tango Therapeutics position peaked at $228K in Q2 2021.
  • 121 funds tracked by Wall St. Rank held Tango Therapeutics as of Q3 2024.

Based on Alaethes Wealth's 13F filing for Q3 2024, filed 14 Nov 2024.